Last $0.66 USD
Change Today 0.00 / 0.00%
Volume 121.2K
MRNA On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 5:20 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

marina biotech inc (MRNA) Snapshot

Open
$0.67
Previous Close
$0.66
Day High
$0.68
Day Low
$0.65
52 Week High
03/13/14 - $1.79
52 Week Low
07/17/14 - $0.48
Market Cap
16.8M
Average Volume 10 Days
107.1K
EPS TTM
$-0.51
Shares Outstanding
25.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MARINA BIOTECH INC (MRNA)

Related News

No related news articles were found.

marina biotech inc (MRNA) Related Businessweek News

No Related Businessweek News Found

marina biotech inc (MRNA) Details

Marina Biotech, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of nucleic acid-based therapies to treat orphan diseases. Its pipeline includes CEQ508 that is in clinical program for the treatment of Familial Adenomatous Polyposis, a hereditary condition; and preclinical programs in type 1 myotonic dystrophy and Duchenne’s muscular dystrophy. The company also has a strategic alliance with Rosetta Genomics, Ltd. to identify and develop microRNA-based products to diagnose and treat various neuromuscular diseases and dystrophies. It has partnering and licensing agreements with Mirna Therapeutics, Inc.; ProNAi Therapeutics, Inc.; Monsanto Company; Avecia Nitto Denko; Novartis Institutes for Biomedical Research, Inc.; Protiva Biotherapeutics Inc.; and Arcturus Therapeutics, Inc. The company was formerly known as MDRNA, Inc. and changed its name to Marina Biotech, Inc. in July 2010. Marina Biotech, Inc. was founded in 1983 and is headquartered in Bothell, Washington.

1 Employees
Last Reported Date: 02/18/15
Founded in 1983

marina biotech inc (MRNA) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $288.1K
Interim Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

marina biotech inc (MRNA) Key Developments

Marina Biotech, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Marina Biotech, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company’s license and other revenue was $500,000 against $2,115,000 a year ago. Loss from operations was $3,520,000 against $365,000 a year ago. Loss before income tax was $6,477,000 against $1,610,000 a year ago. Net loss was $6,477,000 or $0.26 per basic and diluted share against $1,571,000 or $0.09 per basic and diluted share a year ago. Net cash used in operating activities was $4,779,000 against net cash from operating activities was $285,000 a year ago. The change in net loss was due primarily to changes in the fair value of certain liabilities and derivatives, changes in other income and expenses related to debt extinguishment accounting in 2013, and increased operating expenses related to 2014 resumption of business operations.

Marina Biotech, Inc. Auditor Raises 'Going Concern' Doubt

Marina Biotech, Inc. filed its 10-K on Feb 18, 2015 for the period ending Dec 31, 2014. In this report its auditor, Wolf & Company, P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Marina Biotech, Inc. and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics

Marina Biotech, Inc. and MiNA Therapeutics Limited announced that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRNA:US $0.66 USD 0.00

MRNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alnylam Pharmaceuticals Inc $105.40 USD +3.87
Benitec Biopharma Ltd A$0.86 AUD -0.005
Regulus Therapeutics Inc $18.57 USD +0.05
Silence Therapeutics PLC 248.00 GBp 0.00
Tekmira Pharmaceuticals Corp C$22.45 CAD -0.10
View Industry Companies
 

Industry Analysis

MRNA

Industry Average

Valuation MRNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MARINA BIOTECH INC, please visit www.marinabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.